family with sequence similarity 204 member B, pseudogeneGenealiases: []
Q-omics provides the consensus-scored FAM204BP profile across patient tissues and cancer cell-line models. FAM204BP expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in LAML. Among the 18 cancer types available for tumor–normal comparison, FAM204BP is differentially expressed in 4, with the highest sampling consensus in HNSC. Additionally, FAM204BP RNA expression shows 10,850 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight LAML, HNSC, and PDAC as cancer lineages where FAM204BP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM204BP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM204BP survival associations across molecular data types. FAM204BP RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM204BP RNA expression–survival associations across cancer types. High FAM204BP expression shows unfavorable associations in UCS and UVM, but favorable associations in LAML, BLCA, LUAD and STAD. The LAML Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LAML as the clearest survival context for FAM204BP RNA expression.
This table summarizes FAM204BP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for FAM204BP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM204BP shows higher tumor expression in HNSC, COAD, LUAD and BRCA. The HNSC box plot shows higher FAM204BP RNA expression in tumor versus normal tissue (log2 FC = +0.143, t-test p < 0.001).
This table shows molecular features associated with FAM204BP in patient tissues and cancer cell lines. In patient samples, FAM204BP shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set.
